You do not currently have access to this content.
Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had ...
Cancer Res (2023) 83 (7_Supplement): 1143.
Cancer Res (2024) 84 (7_Supplement): CT009. Background: Treatment (tx) for LA SCCHN includes a combination of surgery, radiation and/or chemotherapy followed by monitoring for local recurrence/distant ...
Abstract. MTAP deletions occur in 10-15% of all human cancers, providing one of the largest precision oncology patient populations. MTA-cooperative PRMT5 inhibitors leverage the well-characterized ...
Background: LIV-1, also known as SLC39A6 or ZIP6, is a transmembrane protein belonging to the zinc transporter family. LIV-1 is a promising target for antibody-drug conjugate (ADC) therapy due to its ...
Cancer Res (2025) 85 (8_Supplement_2): CT262. Safety of lunre + cam was analyzed in pts from MYTHIC treated at the RP2D of 80mg BID lunre + 80mg QD cam given 3d on/4d off after individualized schedule ...
Spencer Mirabile-Brightman, Bjoern Peters, Himangshu Sonowal, Zachary Berman, Zev Wainberg, Aaron Miller, Karen Messer, Jiayu Chen, Yago Pico de Coana, Peter Ellmark, Stephen Schoenberger, Rebekah R.
Background: SHR-A1921 is a novel ADC composed of a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) IgG1 monoclonal antibody attached to a DNA topoisomerase I inhibitor via a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results